

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: July 3, 2002

Signature: Shawn P. Foley  
(Shawn P. Foley)

Docket No.: EGYPSA 3.0-004  
(PATENT)

1645  
#8  
BD  
7-19-c2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Patent Application of:  
Legrain et al.

JUL 11 2002

Application No.: 10/043,487

Group Art Unit: 1645 TECH CENTER 1600/2900

Filed: January 11, 2002

Examiner: Not Yet Assigned

For: PROTEIN-PROTEIN INTERACTIONS  
BETWEEN SHIGELLA FLEXNERI  
POLYPEPTIDES AND MAMMALIAN  
POLYPEPTIDES

Commissioner for Patents  
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each reference is enclosed. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: July 3, 2002

Respectfully submitted,

By Shawn P. Foley  
Shawn P. Foley  
Registration No.: 33,071  
LERNER, DAVID, LITTENBERG,  
KRUMHOLZ & MENTLIK, LLP  
600 South Avenue West  
Westfield, New Jersey 07090  
(908) 654-5000  
Attorneys for Applicant



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/043,487		
		Filing Date	January 11, 2002		
		First Named Inventor	Pierre Legrain		
		Art Unit	1645		
		Examiner Name			
Sheet	1	of	3	Attorney Docket Number	EGYPSA 3.0-004

RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	5468614	11-21-1995	Fields et al.	
	AB	5283173	02-01-1994	Fields et al.	
	AC	5667973	09-16-1997	Fields et al.	
	AD	4980286	12-25-1990	Morgan et al.	


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO 00/66722	11-09-2000	Hybrigenics		
	BB	WO 99/42612	08-26-1999	Institut Pasteur		
	BC	WO 00/07038	02-10-2000	Universite de Montreal		
	BD	WO 98/34120	08-06-1998	Universite de Montreal		
	BE	WO 99/28746	06-10-1999	Institut Pasteur		
	BF	WO 92/06180	04-16-1992	University of Connecticut		
	BG	WO 93/14188	07-22-1993	The Regents of the University of Michigan		
	BH	WO 93/20221	10-14-1993	Alexander Young		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	ROBERT SERVICE "Protein arrays step out of DNA's shadow," 289 Science (2000) 16.	
	CB	MACBEATH & SCHREIBER, "Printing proteins as microarrays for high-throughput function determination," 289 Science (2000) 1760-63.	
	CC	ZIJLSTRA et al., "Germ-line transmission of a disrupted $\beta$ 2-microglobulin gene produced by homologous recombination in embryonic stem cells," 342 Letters to Nature (1989) 435-38.	
	CD	WU & WU "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," 262 J. Biol. Chem. (1987) 4429-32.	
	CE	JACOBY et al., "Hybrid vectors: a new generation of virus-based vectors designed to control the cellular fate of delivered genes," 4 Gene Therapy (1997) 1281-83.	
	CF	STEPHEN KOCHANNEK, "High-capacity adenoviral vectors for gene transfer and somatic gene therapy," 10 Human Gene Therapy (1999) 2451-59.	
	CG	MILLER et al., "Use of Retroviral Vectors for Gene Transfer and Expression," 217 Methods in Enzymology Recombinant DNA Part H (1993) 581-99.	
	CH	ROBBINS & GHIVIZZANI "Viral Vectors for Gene Therapy," 80 Pharmacology & Therapeutics (1998) 35-47.	



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **3**

### Complete If Known


Application Number	10/043,487
Filing Date	January 11, 2002
First Named Inventor	Pierre Legrain
Art Unit	1645
Examiner Name	
Attorney Docket Number	EGYPSA 3.0-004

RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CI	CAVANAUGH et al. "The neurotoxin of shigella shigae. A comparative study of the effects produced in various laboratory animals," 37 British J. Experimental Pathology (1956) 272-78.	
	CJ	TAKACS et al. "Mapping of interacting domains between the nucleocapsid protein and the phosphoprotein of vesicular stomatitis virus by using a two-hybrid system," 90 Proc. Natl. Acad. Sci. (1993) 10375-79.	
	CK	SZABO et al. "Surface plasmon resonance and its use in biomolecular interaction analysis (BIA) 5 Current Opinion in Structural Biology (1995) 699-705.	
	CL	PEARSON & LIPMAN "Improved tools for biological sequence comparison," 85 Proc. Natl. Acad. Sci. (1988) 2444-8.	
	CM	NEEDLEMAN & WUNSCH, "A general method applicable to the search for similarities in the amino acid sequence of two proteins," 48 J. Molecular Biology (1970) 443-53.	
	CN	SMITH & WATERMAN "Overlapping genes and information theory" Letter to the Editor, 91 J. Theoretical Biology (1981) 379-80.	
	CO	BRENT & FINLEY "Understanding gene and allele function with two-hybrid methods," 31 Annual Review of Genetics (1997) 663-704.	
	CP	LEGRAIN & SELIG "Genome-wide protein interaction maps using two-hybrid systems," 480 FEBS Letters (2000) 32-36.	
	CQ	VIDAL & LEGRAIN "Yeast forward and reverse 'n'-hybrid systems," 27 Nucleic Acids Research (1999) 919-29.	
	CR	EDWARDS & LEATHERBARROW "Determination of Association rate constants by an optical biosensor using initial rate analysis," 246 Analytical Biochemistry (1997) 1-6.	
	CS	GOLDSPIEL et al. "Clinical Frontiers; Human gene therapy," 12 Clin. Pharm. (1993) 488-505.	
	CT	FIELDS & SONG "A novel genetic system to detect protein-protein interactions," 340 Nature (1989) 245-6.	
	CU	REYNOLDS et al., "Chimeric viral vectors -- the best of both worlds?" Molecular Medicine Today (1999) 25-31.	
	CV	VIDAL et al. "Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-protein and DNA-protein interactions" 93 Proc. Natl. Acad. Sci USA (1996) 10315-20.	
	CW	TIRODE et al. "A conditionally expressed third partner stabilizes or prevents the formation of a transcriptional activator in a three-hybrid system," 272 J. Biol. Chemistry (1997) 22995-99.	
	CX	BRENNER et al. "Polynucleotide sequence relatedness among shigella species," 23 Int'l J. Systematic Bacteriology (1973) 1-7.	
	CY	LABREC et al. "Epithelial cell penetration as an essential step in the pathogenesis of bacillary dysentery," 88 J. Bacteriology (1964) 1503-18	
	CZ	FORMAL et al "Invasive Enteric Pathogens," Reviews of Infectious Diseases (1983) S702-7	
	CA1	ROUT et al "Pathophysiology of shigella diarrhea in the rhesus monkey: intestinal transport, morphological and bacteriological studies," 68 Gastroenterology (1975) 270-78.	
	CB1	TAKEUCHI et al. "Experimental acute colitis in the rhesus monkey following peroral infection with shigella flexneri," 52 Am. J. Pathology (1968) 503-529.	
	CC1	TAKEUCHI et al. "Experimental bacillary dysentery," 47 Am. J. Pathology (1968) 1011-44	
	CD1	KINSEY et al. "Fluid and electrolyte transport in rhesus monkeys challenged intracably with shigella flexneri 2a," 14 Infection & Immunity (1976) 368-71.	
	CE1	GIANANTONIO et al. "The hemolytic-uremic syndrome," 64 J. Pediatrics 478-491	
	CF1	KOSTER et al. "Hemolytic-uremic syndrome after shigellosis," 298 New England J. Med. (1978) No. 17 p. 927-33.	
	CG1	CONRADI et al., "Ueber iosliche durch aseptische autolyse erhaltene gitstoffe von ruhr und typhusbazillen," Medicinische Wochenschrift (1903)	
	CH1	KEUSCH and JACEWICZ, "The pathogenesis of shigella diarrhea..." 135 J. Infectious Diseases (1977) 552-556.	
	CI1	OBRIEN & HOLMES, "Shiga and Shiga-Like Toxins," 51 Microbiol. Rev's (1987) 206-220.	
	CJ1	SANSONETTI et al. "Shigella sonnei plasmids: evidence that a large plasmid is necessary for virulence," 34 Infection and Immunity (1981) 75-83.	



PTO/SB/08B (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/043,487
		Filing Date	January 11, 2002
		First Named Inventor	Pierre Legrain
		Art Unit	1645
		Examiner Name	
		Attorney Docket Number	EGYPSA 3.0-004
Sheet	3	of	3
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	CK1	SANSONETTI et al. "Alterations in the pathogenicity of escherichia coli K-12 after transfer of plasmid and chromosomal genes from shigella flexneri," 39 Infection and Immunity (1983) 1392-1402.	
	CL1	CLERC et al., "Plasmid-Mediated early killing of eucaryotic cells by shigella flexneri as studied by infection of J774 macrophages," 55 Infection and Immunity (1987) 521-7.	
	CM1	CLERC and SANSONETTI, "Entry of shigella flexneri into hela cells: evidence for directed phagocytosis involving actin polymerization and myosin accumulation" 55 Infection and Immunity (1987) 2681-88.	
	CN1	MOYER et al., "Cytotoxicity of shiga toxin for primary cultures of human colonic and ileal epithelial cells," 55 Infection and Immunity (1987) 1533-35.	
	CO1	BRIDGEWATER et al "The neurotoxin of shigella shigae..." 36 Brit. J. Experimental Pathology (1955) 447-453.	
	CP1	LUPSKI & FEIGIN "Molecular evolution of pathogenic escherichia coli," 157 J. Infectious Diseases (1988) 1120-23.	
	CQ1	MYRON M. LEVINE "Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent," 155 J. Inf. Diseases (1987) 377-89.	
	CR1	MOHAMED A. KARMALI, "Infection by verocytotoxin-producing escherichia coli," 2 Clin. Microbiology Reviews (1989) 15-38.	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

RECEIVED  
JUL 11 2002  
TECH CENTER 1600/2900